Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study

Limited treatment options are available for relapsed or refractory diffuse large B cell lymphoma (RR DLBCL). Few clinical studies have reported the use of Ibrutinib, a covalent Bruton Tyrosine kinase (BTK) inhibitor, in RR DLBCL. There are relatively few clinical studies about Ibrutinib in RR DLBCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Liangliang, Li, Ling, Zhang, Lei, Li, Xin, Fu, Xiaorui, Wang, Xinhua, Wu, Jingjing, Sun, Zhenchang, Feng, Xiaoyan, Chang, Yu, Zhou, Zhiyuan, Nan, Feifei, Yan, Jiaqin, Kong, Fei, Zhang, Mingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804031/
https://www.ncbi.nlm.nih.gov/pubmed/35115740
http://dx.doi.org/10.1007/s12288-021-01433-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804031/
https://www.ncbi.nlm.nih.gov/pubmed/35115740
http://dx.doi.org/10.1007/s12288-021-01433-w

Ejemplares similares